TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The TESLA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke
Brief Summary: The primary objective of the trial is to establish the effectiveness of IAT (versus medical management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with adaptive enrichment to better define the upper limit of infarct volume for treatment eligibility. Furthermore, the investigators aim to determine whether certain subgroups of patients with large baseline infarcts will have a greater treatment benefit. Finally, the investigators will assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.


Options:
A: Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intra-arterial Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Intra-arterial Therapy | Intervention Type: PROCEDURE; Name: Intra-arterial Therapy; Assigned to Arm(s): Intra-arterial Therapy
B: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
C: Arm Label: endovascular thrombectomy therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Thrombectomy, Device: Trevo Retriever, Device: Solitaire™ FR Revascularization Device, Device: Penumbra thrombectomy system, Device: Covidien MindFrame Capture Revascularization Device | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Endovascular Thrombectomy; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Trevo Retriever; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Solitaire™ FR Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Penumbra thrombectomy system; Assigned to Arm(s): endovascular thrombectomy therapy | Intervention Type: DEVICE; Name: Covidien MindFrame Capture Revascularization Device; Assigned to Arm(s): endovascular thrombectomy therapy
D: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of an Innovative Continuing Professional Development Intervention on Rehabilitation Clinicians' Practices to Improve Walking and Independence in Activities of Daily Living After Stroke: a Pilot Study
Brief Summary: The overall aim of this pilot study is to evaluate the feasibility of a study protocol for a future stepped wedge cluster randomized clinical trial (c-RCT) that will investigate the effects of an innovative KT intervention on 1) walking capacity and independence in ADL in patients undergoing rehabilitation after stroke (patient outcomes); and 2) clinicians' practice (i.e. use of 4 evidence-based stroke rehabilitation interventions: motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task oriented training including fitness and mobility exercises and aerobic training) (provider outcome) aimed at improving walking capacity. The specific objectives are: 1) To evaluate the feasibility (effectiveness of clinician recruitment strategies, extent of losses to follow-up across sites, and data analysis plans) of the study protocol in terms of methodology (stepped wedge design is an innovative methodology); 2) To estimate intervention effect sizes on study outcomes (patient and clinician); 3) To evaluate the secondary outcome (clinicians' use of the 4 interventions) with regard to reliability and validity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
D: Arm Label: an intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Behaviour Change Wheel model guided intervention | Arm Label: a control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behaviour Change Wheel model guided intervention; Assigned to Arm(s): an intervention arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of an Innovative Continuing Professional Development Intervention on Rehabilitation Clinicians' Practices to Improve Walking and Independence in Activities of Daily Living After Stroke: a Pilot Study
Brief Summary: The overall aim of this pilot study is to evaluate the feasibility of a study protocol for a future stepped wedge cluster randomized clinical trial (c-RCT) that will investigate the effects of an innovative KT intervention on 1) walking capacity and independence in ADL in patients undergoing rehabilitation after stroke (patient outcomes); and 2) clinicians' practice (i.e. use of 4 evidence-based stroke rehabilitation interventions: motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task oriented training including fitness and mobility exercises and aerobic training) (provider outcome) aimed at improving walking capacity. The specific objectives are: 1) To evaluate the feasibility (effectiveness of clinician recruitment strategies, extent of losses to follow-up across sites, and data analysis plans) of the study protocol in terms of methodology (stepped wedge design is an innovative methodology); 2) To estimate intervention effect sizes on study outcomes (patient and clinician); 3) To evaluate the secondary outcome (clinicians' use of the 4 interventions) with regard to reliability and validity.


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Other: Implementation of stroke mobility guidelines | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of stroke mobility guidelines; Assigned to Arm(s): Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Clinical Pathways | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Pathways; Assigned to Arm(s): 1
C: Arm Label: TCM integrated group; Type: ACTIVE_COMPARATOR; Interventions: Other: acupuncture, massage and basic TCM treatment | Arm Label: Western Medicine group; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation and WM basic treatment | Intervention Type: OTHER; Name: acupuncture, massage and basic TCM treatment; Assigned to Arm(s): TCM integrated group | Intervention Type: OTHER; Name: rehabilitation and WM basic treatment; Assigned to Arm(s): Western Medicine group
D: Arm Label: Pre-intervention group (Control group); Type: N/A; Interventions: N/A | Arm Label: Post-intervention group (Training course group); Type: N/A; Interventions: Other: training of emergency professionals to acute stroke management | Intervention Type: OTHER; Name: training of emergency professionals to acute stroke management; Assigned to Arm(s): Post-intervention group (Training course group)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Empower Breastfeeding: Effects of an Integrated Breastfeeding Education Program on Optimal Breastfeeding Practice
Brief Summary: This study results of integrated breastfeeding education program (IBEP) will guide in designing a theory-based breastfeeding educational module on promotion of optimal breastfeeding practice in new mother and her partner. The current novel education curriculum incorporated breastfeeding simulation, mindfulness training, and professional support will provide important information in supporting use of IBEP in enhancing participants self-efficacy. This study will show on how simulation teaching and mindfulness training can be utilized in the field of perinatal teaching to achieve better health outcomes.


Options:
A: Arm Label: Telelactation support; Type: EXPERIMENTAL; Interventions: Behavioral: Telelactation services | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telelactation services; Assigned to Arm(s): Telelactation support
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Simulation breastfeeding education | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Simulation breastfeeding education; Assigned to Arm(s): Intervention Group
C: Arm Label: Breastfeeding Education and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding Education and Support | Arm Label: Usual or routine care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding Education and Support; Assigned to Arm(s): Breastfeeding Education and Support
D: Arm Label: Lactation Consultant; Type: ACTIVE_COMPARATOR; Interventions: Other: Lactation Consultant support | Arm Label: current treatment for jaundice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Lactation Consultant support; Assigned to Arm(s): Lactation Consultant

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Non-interventional Cross-sectional Study to Capture the Prevalence of Cardiovascular Disease in Patients With Type 2 Diabetes - an International Observation
Brief Summary: The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes patients across ten countries across the world. Participants will be asked to give information about their health. Participants will continue their normal way of life and will not get any medication other than prescribed to them by their doctor. Participants' participation will be one day/one visit at their doctor. The study will last for about 6 months in total.


Options:
A: Arm Label: Telecare; Type: EXPERIMENTAL; Interventions: Other: Telecare | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Intervention Type: OTHER; Name: Telecare; Assigned to Arm(s): Telecare | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): Conventional therapy
B: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention
D: Arm Label: Participants with type 2 diabetes mellitus (T2DM); Type: N/A; Interventions: Other: No treatment given | Intervention Type: OTHER; Name: No treatment given; Assigned to Arm(s): Participants with type 2 diabetes mellitus (T2DM)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes; Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients. The Hypo-energetic Study.
Brief Summary: Scientific evidence for the dietary treatment of type 2 diabetes (T2D) is insufficient, which is why the investigators aim to reform dietary recommendation to the overweight or obese patient with type 2 diabetes. This clinical study will examine the effect of a highly controlled hypo-energetic carbohydrate-reduced high-protein (CRHP) diet intervention under caloric restriction-induced body weight loss as a treatment modality in T2D. The investigators hypothesize that this intervention compared to the conventional diabetes (CD) diet with similar loss in body weight improves metabolic control and cardiovascular risk profile in T2D by:

* Reducing diurnal and postprandial glycaemia, thereby facilitating a significant reduction in HbA1c
* Reducing ectopic lipid deposits in liver, muscle and pancreas
* Improving lipid profile towards a less atherogenic profile
* Improving metabolic actions of insulin, through increased sensitivity and β-cell function
* Reducing diurnal blood pressure with no adverse effect on heart rate variability


Options:
A: Arm Label: CRHP Diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: CRHP Diet | Arm Label: CD Diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: CD Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: CRHP Diet; Assigned to Arm(s): CRHP Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: CD Diet; Assigned to Arm(s): CD Diet
B: Arm Label: Low-carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-carbohydrate diet | Arm Label: Low-fat diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: low-fat diet | Intervention Type: BEHAVIORAL; Name: low-carbohydrate diet; Assigned to Arm(s): Low-carbohydrate diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): Low-fat diet
C: Arm Label: Low-Carb High-Fat Breakfast; Type: EXPERIMENTAL; Interventions: Other: Low-Carb High-Fat breakfast | Arm Label: Low fat "Standard Care" Control Breakfast; Type: ACTIVE_COMPARATOR; Interventions: Other: Low fat "standard care" control breakfast | Intervention Type: OTHER; Name: Low-Carb High-Fat breakfast; Assigned to Arm(s): Low-Carb High-Fat Breakfast | Intervention Type: OTHER; Name: Low fat "standard care" control breakfast; Assigned to Arm(s): Low fat "Standard Care" Control Breakfast
D: Arm Label: Low-Carbohydrate Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low-Carbohydrate Diet | Arm Label: Usual Diet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Low-Carbohydrate Diet; Assigned to Arm(s): Low-Carbohydrate Diet

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial
Brief Summary: The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).


Options:
A: Arm Label: Continue adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Stop adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Continue adalimumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Stop adalimumab
B: Arm Label: Double-Blind Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: Double-Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: OLE BSA Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE BSA Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo + MTX; Assigned to Arm(s): Double-Blind Adalimumab + MTX, Double-Blind Placebo + MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo; Assigned to Arm(s): Double-Blind Adalimumab, Double-Blind Placebo | Intervention Type: DRUG; Name: OLE BSA Adalimumab +/- MTX; Assigned to Arm(s): OLE BSA Adalimumab, OLE BSA Adalimumab + MTX | Intervention Type: DRUG; Name: OLE FD Adalimumab +/- MTX; Assigned to Arm(s): OLE FD Adalimumab, OLE FD Adalimumab + MTX
C: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti-tumor necrosis factor alpha monoclonal antibody; Assigned to Arm(s): adalimumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: CNTO 148 (Golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 148 (Golimumab), Drug: Methotrexate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: CNTO 148 (Golimumab); Assigned to Arm(s): CNTO 148 (Golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): CNTO 148 (Golimumab), Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Double-blind, Parallel Group, Multicenter Study to Evaluate Further Therapeutic Strategies With Guselkumab in Patients With Moderate-to-Severe Plaque-Type Psoriasis
Brief Summary: The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).


Options:
A: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
D: Arm Label: Part 1: Guselkumab; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab | Arm Label: Part 2: Guselkumab q8w and Guselkumab q16w; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab | Arm Label: Part 2: Guselkumab q8w; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo Injection | Arm Label: Part 3: Guselkumab Withdrawal; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Part 1: Guselkumab, Part 2: Guselkumab q8w, Part 2: Guselkumab q8w and Guselkumab q16w, Part 3: Guselkumab Withdrawal | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Part 2: Guselkumab q8w

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Value of Tranxemic Acid to Reduce Intraoperative Blood Loss During Elective Cesarean Sections in High Risk Women: A Randomized Controlled Trial
Brief Summary: A full medical history will be obtained from all participants. Obstetric ultrasonography and laboratory tests will be performed.According to group assignment, either 1 g(10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose or 30 mL of 5% glucose will be slowly administered intravenously 15 minutes before skin incision over a 5-minute period.

Following delivery, patients in both groups will receive an intravenous bolus of 5 IU oxytocin , 1 mL(0.2 mg) intramuscular ergometrine , and 20 IU oxytocin in 500 mL lactated Ringer's solution(infused at a rate of 125 mL/h)


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
B: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
C: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Tranexamic acid group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid, Procedure: Cesarean section | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Cesarean section | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid group | Intervention Type: PROCEDURE; Name: Cesarean section; Assigned to Arm(s): Control group, Tranexamic acid group

Answer: D